About Event
Welcome to the 4th Gene Therapy Analytical Development Europe Summit
As gene therapy biopharma wrestles to demonstrate clinical efficacy and product safety, the need to develop robust and efficient analytical tools has never been greater. In the face evolving regulatory guidelines and mounting scrutiny, the 4th Gene Therapy Analytical Development Europe Summit will showcase best-in-class data and case study driven content to ensure you can develop sound analytical tools that guarantee the consistency, quality and safety of your gene therapy product and ultimately support your product getting to the market faster.
Uniting leading CMC, Regulatory, QC, Analytical and Process Development experts, the 4th Gene Therapy Analytical Development Europe Summit is the industry’s definitive and only meeting focused on tackling the greatest analytical development challenges in the context of gene therapy drug development.

“Most efficient way to get updated on new developments in the field and meet fellow scientists, Contract service providers and procedures of novel equipment for GTMP analytics” – Amarna Therapeutics
Join Your Peers in Person to:

Evaluate the current regulatory expectations for product-release testing to ensure your gene therapy meets the current criteria around quality, purity, and strength

Determine the advantages of orthogonal methods (AUC, SEC-MALS), for the accurate assessment of empty:full capsids to guarantee efficacy and safety of AAV vector products

Discover the new and improved genome quantification methods for late-stage clinical development to accurately quantify transgene expression and inform clinical dosing decisions

Explore the movement towards automation of analytics to reduce resource burden and improve sensitivity and efficiency of analytical data generation

Uncover the analytical tools being leveraged for non AAV gene therapies to navigate the nuanced complexities when characterizing gRNAs and ribonucleoproteins for CRISPR applications

Review the next generation tools for Host Cell Protein Detection and quantification to mitigate risk in gene therapy development

Assess how analytical comparability strategies can be leveraged to strengthen process development

Navigate the challenges of working with limited volumes of material